Reappraisal of Coronavirus Disease 2019 Risk for Patients With Inflammatory Bowel Disease: Withdrawal of the British Society of Gastroenterology Inflammatory Bowel Disease Risk Grid.

Authors:
Ungaro RC; Kappelman MD.

Journal:
Gastroenterology

Publication Year: 2022

DOI:
10.1053/j.gastro.2022.09.015

PMCID:
PMC9514020

PMID:
36162590

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Gastroenterology

Abbreviation: Gastroenterology

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Apposition of Fibroblasts With Metaplastic Gastric Cells Promotes Dysplastic Transition.
Lee SH; Contreras Panta EW; Gibbs D and 20 more (2023) - Transparency Score: 3/6
Elucidating the Risk of Colorectal Cancer for Variants in Hereditary Colorectal Cancer Genes.
Mahmood K; Thomas M; Qu C and 4 more (2023) - Transparency Score: 3/6
Repurposing UDCA, an FXR Inhibitor, to Prevent SARS-Cov-2 Infection.
Prayitno K; Bhat M. (2023) - Transparency Score: 2/6
RNA Sequencing Identifies Frequent Mitogen-activated Protein Kinase-associated Fusion Genes in Intr…
Lee JW; Hruban RH; Brosens LAA and 4 more (2023) - Transparency Score: 3/6
The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases.
Fogelson KA; Dorrestein PC; Zarrinpar A and 1 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest The authors disclose the following: Ryan C. Ungaro has served as an advisory board member or consultant for AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda and has received research support from 10.13039/100006483AbbVie , Boehringer Ingelheim , Eli Lilly , and 10.13039/100004319Pfizer . Michael D. Kappelman has consulted for 10.13039/100006483Abbvie , Janssen, 10.13039/100004319Pfizer , Takeda , and Lilly; is a shareholder in Johnson & Johnson; and has received research support from 10.13039/100004319Pfizer , Takeda , Janssen, 10.13039/100006483Abbvie , Lilly , 10.13039/100004328Genentech , Boehringer Ingelheim , Bristol Myers Squibb , Celtrion, and Arenapharm."

Evidence found in paper:

"Funding None."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025